期刊
DIGESTIVE DISEASES
卷 33, 期 4, 页码 504-507出版社
KARGER
DOI: 10.1159/000374098
关键词
Hepatic fibrosis; Stellate cells; Metalloproteinases; Tissue inhibitors of metalloproteinases; Antifibrotics; Cirrhosis; Fibrogenesis; Macrophages
There has been tremendous progress made in understanding the pathogenesis of hepatic fibrosis, which has created new opportunities for the treatment of this condition. Clinical evidence of fibrosis reversibility has established that the liver has the capacity to resorb scar tissue, and future therapies will be based in part on this insight. Additionally, the paradigm of hepatic stellate cell activation provides an important template for defining targets of antifibrotic therapy. Opportunities abound to accelerate drug approvals once biomarkers are improved and endpoints of clinical trials are better defined. Overall, there is heartening evidence that fibrosis is a tractable consequence of chronic liver disease that will be amenable to therapy even when the underlying disease has not been cured. (C) 2015 S. Karger AG, Basel
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据